Search Results
34 Results Found for “tirzepatide”
In response to the increasing prevalence of obesity, the consumption of high-calorie and high-sugar foods and an unprecedented aging population, type 2 diabetes (T2D) continues to rise globally. The International Diabetes Federation reported that 589 million individuals aged 20 to 79 years had ...
Type 2 diabetes (T2D) is a progressive metabolic condition associated with obesity, cardiovascular disease and substantial morbidity and mortality.1 Despite the availability of multiple glucose-lowering therapies, a significant proportion of individuals with T2D fail to achieve recommended glycemic targets, ...
Data presented at ENDO 2026 highlighted investigational approaches for difficult-to-control type 2 diabetes and acquired hypothalamic obesity, real-world outcomes with tirzepatide, and wider health impacts of GLP-1-based therapy.
In this interview, Diana Isaacs shares her highlights from the 2026 AACE Annual Meeting, discussing key advances in diabetes management, obesity treatment and diabetes technology, alongside emerging priorities for future endocrinology research and guideline development.
Dr Ahmed Iqbal joins the touchREVIEWS in Endocrinology Editorial Board, bringing expertise in hypoglycaemia and personalized diabetes care.
In this roundup, members of the touchNDOCRINOLOGY Expert Faculty share their perspectives on the advances that shaped research and practice over the past year, highlighting a discipline in transition and looking ahead to the opportunities of 2026.
GLP-1 receptor agonists have been a standout development this year, reshaping the treatment of type 2 diabetes and obesity. In this expert perspective, Glenn D Braunstein highlights their expanding benefits, from weight loss and cardiometabolic protection to emerging dual- and tri-agonist therapies, while also addressing key challenges as these agents move rapidly into mainstream clinical practice.
Post-bariatric weight regain is a major clinical challenge. In the BARI-STEP trial, semaglutide 2.4 mg weekly led to substantial, sustained weight loss and improved cardiometabolic health. Dr Janine Makarondis discusses the findings and the potential of GLP-1 therapy in this patient population.
ObesityWeek® 2025 highlighted obesity as a chronic, multi-system disease that links cardiovascular, renal, and metabolic health. New data from clinical trials showcased therapies improving weight, blood pressure, and inflammation, signalling a shift toward integrated care where obesity management becomes central to cardiovascular-kidney-metabolic health.
Dr John Doupis shares his highlights from EASD 2025, discussing breakthrough trials in diabetes and obesity, emerging therapies, and how advancing technology and AI are reshaping the future of diabetes care.
Fatty liver is the largest liver disease globally and has become a leading cause of liver cirrhosis and end-stage liver disease. Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic steatohepatitis (NASH), affects about one-third of the adult population ...
TouchENDOCRINOLOGY coverage from EASD 2025: At the EASD 2025 congress (Vienna, Austria; 15–19 September), new research from the University of Sheffield explored the potential role of tirzepatide as an adjunctive therapy in people with type 1 diabetes and obesity. Tirzepatide, a dual GIP and ...
We spoke with Dr Garvey at EASD 2025 to learn more about the mechanism of action of cagrilintide, the design and outcomes of the REDEFINE 1 analysis, and the future directions for this promising therapeutic option.
At EASD 2025, the phase 2 TIRTLE1 trial showed tirzepatide significantly reduced weight, insulin needs and improved glycaemic control in adults with type 1 diabetes and obesity. In this interview, Dr Jennifer Snaith discusses the findings and clinical implications.
This Q&A with Dr Paul Brennan offers a practical guide to the diagnosis and management of metabolic dysfunction-associated steatohepatitis (MASH). Covering key risk factors, non-invasive diagnostic tools, lifestyle strategies, and emerging therapies, it provides clinicians with clear approaches to early detection and comprehensive patient care.
In this Future Leader Q&A, Dr Jennifer Snaith shares her journey as a clinician-scientist in type 1 diabetes, reflecting on mentorship, clinical trial innovation, and the vital role of patients in shaping research and care.
Article highlights There is growing clinical importance attributed to the development of metabolic dysfunction-associated steatotic liver disease in people with type 2 diabetes (T2D). Numerous international groups now advocate screening for advanced fibrosis in people with risk factors, such as ...
The 3-year results from the SURMOUNT-1 trial, published in the New England Journal of Medicine, have revealed that tirzepatide significantly reduced the risk of progression to type 2 diabetes (T2D) in individuals with obesity and prediabetes. T2D onset was ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
